[Temporary Announcement] Zhengke Pharmaceutical: Announcement of Resolutions of the 10th Meeting of the Fourth Board of Directors
Announcement number: 2026-018
Securities code: 836342 Securities abbreviation: Zhengke Pharmaceutical Sponsoring broker: GF Securities
Nanjing Zhengke Pharmaceutical Co., Ltd.
Announcement of Resolutions of the Tenth Meeting of the Fourth Board of Directors
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.
1. Meeting convening and attendance
(1) Meeting status
Meeting time: April 27, 2026
Meeting method: √On-site meeting □Electronic communication meeting
Meeting place: company conference room
Time and method of issuing board meeting notice: in writing on April 23, 2026 5. Meeting host: Chairman Mr. Lu Rongzheng
Meeting attendees: senior managers
Explanation on the legality and compliance of the convening situation:
The convening and holding of this meeting complied with the provisions of the Company Law and the Articles of Association, and the resolutions made were legal and valid.
(2) Meeting attendance
The meeting should be attended by 5 directors, and 5 directors should be present and authorized to attend.
2. Proposal review status
(1) Consideration and approval of the "Proposal on the Company's 2025 Annual Profit Distribution Plan (Revised Version)" 1. Contents of the proposal:
Since the company's related work needs to be reorganized, it is planned to revise the company's original "2025 Annual Plan"
Announcement number: 2026-018
Profit Distribution Plan".
Based on the company's operating performance and financial status in 2025, as well as its future development plan, the annual profit distribution plan for 2025 (revised version) is now proposed.
The company's current total share capital is 72,818,200 shares. It plans to use the number of shares that should be distributed on the equity registration date when the equity distribution is implemented as the base, and distribute a cash dividend of RMB 10.00 (tax included) to all shareholders for every 10 shares based on undistributed profits. 2. Avoidance of voting:
This proposal does not involve related party transactions and there is no need to avoid voting.
Voting results for the motion: 5 votes in favor; 0 votes against; 0 abstentions.
Submit the voting status of the shareholders’ meeting:
This proposal still needs to be submitted to the shareholders' meeting for review.
(2) Consideration and approval of the "Proposal on Adjusting the Quota for Using Idle Own Funds to Purchase Financial Management Products in 2026" 1. Contents of the proposal:
The company held the seventh meeting of the fourth board of directors on December 3, 2025, and the third extraordinary shareholders' meeting of 2025 on December 18, 2025. The company reviewed and approved the "Proposal on Using Idle Own Funds to Purchase Financial Management Products in 2026", and the resolution passed that the company will use idle funds not exceeding RMB 80 million to purchase short-term financial products from banks and other financial institutions. For details, see the company's 2025 The "Announcement on the Use of Idle Own Funds to Purchase Financial Management Products in 2026" (Announcement Number: 2025-049) was disclosed on the National Small and Medium-sized Enterprises Share Transfer System Information Disclosure Platform (www.neeq.com.cn) on December 3, 2026.
Now, based on its own capital situation and future capital arrangement plan, the company has adjusted and increased the amount of idle self-owned funds for purchasing financial products from RMB 80 million to RMB 140 million. The investment limit includes the amount of reinvested investment income. Within the above limit, the funds can be recycled.
- Avoidance of voting:
This proposal does not involve related party transactions and there is no need to avoid voting.
Voting results for the motion: 5 votes in favor; 0 votes against; 0 abstentions.
Submit the voting status of the shareholders’ meeting:
This proposal does not need to be submitted to the shareholders' meeting for review.
(3) Consideration and approval of the “Proposal on Proposing to Convene the Second Extraordinary Shareholders’ Meeting in 2026”
Announcement number: 2026-018
- Contents of the motion:
The company plans to hold the second extraordinary shareholders' meeting of 2026 on May 13, 2026 to review the above matters. 2. Avoidance of voting:
This proposal does not involve related party transactions and there is no need to avoid voting.
Voting results for the motion: 5 votes in favor; 0 votes against; 0 abstentions.
Submit the voting status of the shareholders’ meeting:
This proposal does not need to be submitted to the shareholders' meeting for review.
3. Documents for reference
"Resolution of the 10th Meeting of the Fourth Board of Directors of Nanjing Zhengke Pharmaceutical Co., Ltd."
Board of Directors of Nanjing Zhengke Pharmaceutical Co., Ltd.
April 27, 2026